171 patents
Utility
Phosphorothioate-conjugated miRNAs and methods of using the same
2 Jan 24
Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3′ end to a phosphorothioate polymer.
Andreas Herrmann, Hua Yu
Filed: 30 Mar 21
Utility
PARG inhibitors and method of use thereof
2 Jan 24
Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.
Xiaochun Yu, Shih-Hsun Chen, Yate-Ching Yuan, Hongzhi Li, David Horne
Filed: 22 Jun 18
Utility
Expression system for expressing herpesvirus glycoprotein complexes
19 Dec 23
An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex.
Felix Wussow, Don J. Diamond
Filed: 9 Jun 22
Utility
Aptamer compositions and the use thereof
19 Dec 23
Provided are aptamer compositions and their use for treating cancer.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 31 Mar 17
Utility
Recombinant adeno-associated vectors for targeted treatment
5 Dec 23
Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 11 Feb 20
Utility
Methods of quantifying methylglyoxal-induced nucleic acid adducts
5 Dec 23
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Timothy W. Synold, John Termini, Sarah Shuck
Filed: 31 Jul 20
Utility
Methods of using anti-MIR126 compounds
31 Oct 23
Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds.
Guido Marcucci, Bin Zhang, Ya-Huei Kuo, Marcin Tomasz Kortylewski
Filed: 5 Mar 20
Utility
DNA2 inhibitors for cancer treatment
10 Oct 23
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 29 Oct 21
Utility
Compositions and methods for mitochondrial genome editing
10 Oct 23
Compositions and methods for mitochondria genome editing are provided.
John Burnett, Anh Pham
Filed: 9 Jun 17
Utility
Cleaning device for blood vessel sealing apparatus
3 Oct 23
A cleaner device is adapted to clean a blood vessel sealer device.
Gagandeep Singh
Filed: 9 Jul 21
Utility
T-cell lymphoma treatments
26 Sep 23
Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound.
David Horne, Sangkil Nam
Filed: 15 Jun 18
Utility
Recombinant lectin and uses thereof
26 Sep 23
Disclosed herein are a recombinant Streptomyces S27S5 hemagglutinin (SHA), and homologues thereof, and a fusion protein of a fluorescent protein (such as GFP and mCherry1) and SHA or a homologue thereof, which specifically bind to carbohydrates, including oligomeric sugars that terminate in L-rhamnose or D-galactose.
Markus Kalkum, Yoko Fujita-Yamaguchi, Karine Bagramyan, Teresa B. Hong, Sarah Shuck
Filed: 4 Aug 21
Utility
Short hairpin RNA compositions, methods of making and applications thereof
26 Sep 23
Provided herein are novel synthetic short hairpin RNA (shRNA) molecules and compositions and kits comprising such molecules, as well as methods of making and using these molecules, compositions, and kits.
Guihua Sun
Filed: 16 Oct 20
Utility
Splice inhibiting oligonucleotides
26 Sep 23
Provided herein are, inter alia, oligonucleotides, kits, and methods useful for increasing lentiviral titers.
John C. Burnett, Elizabeth Epps, John J. Rossi
Filed: 28 Jul 21
Utility
TKI permeability enhancers
19 Sep 23
Provided herein are, inter alia, methods useful for delivering nucleic acids and kinase inhibitors to a cell.
Cy Aaron Stein, Daniela Castanotto, David Horne
Filed: 17 Nov 15
Utility
Cancer detection and ablation system and method
12 Sep 23
Systems and methods are configured to detect and/or ablate cancerous tissue, such as during surgery.
Yuman Fong, Michael Storrie-Lombardi, Veronica Jones, Daniel Schmolze, Lily L. Lai, Ragini Kothari
Filed: 30 Apr 19
Utility
CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis
5 Sep 23
Methods for treating AL amyloidosis using chimeric antigen receptors targeting CS1 are described.
Xiuli Wang, Stephen J. Forman
Filed: 20 Mar 18
Utility
Cell penetrating antibodies
22 Aug 23
Provided herein are cell penetrating conjugates.
Andreas Herrmann, Hua Yu
Filed: 15 Jan 16
Utility
CS1 targeted chimeric antigen receptor-modified T cells
22 Aug 23
Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
Xiuli Wang, Stephen J. Forman
Filed: 13 Aug 20
Utility
Methods, compositions, and kits for detection of aspergillosis
15 Aug 23
Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods.
Markus Kalkum, Karine Bagramyan, Diana Diaz-Arevalo, James I. Ito, Sanjeet Dadwal
Filed: 11 May 20